☆ 4.7 Article

Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras

JOURNAL OF MEDICINAL CHEMISTRY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Chemistry, Medicinal

Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation

Hualin Zhang et al.

Summary: A series of EGFR proteolysis-targeting chimeras (PROTACs) were designed and synthesized to induce degradation of EGFR C797S mutant in resistant non-small cell lung cancer patients, with compound 6h showing promising degradation and antiproliferation activity.

ACS MEDICINAL CHEMISTRY LETTERS (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy

Shi Shi et al.

Summary: This study reports the discovery of a Dacomitinib-based EGFR degrader that can effectively induce degradation of EGF (Rdel19) and shows promising antitumor efficacy without causing observable toxic effects in vivo.

BIOORGANIC CHEMISTRY (2022)

添加到收藏夹

Article Chemistry, Medicinal

Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer

Matin Shaikh et al.

Summary: Osimertinib, a pyrimidine core-containing compound, is the only third-generation EGFR-TKI approved to target T790M resistance, but the C797S mutation may hamper its efficacy. Further research on overcoming resistance mechanisms is needed for effective treatment of NSCLC patients.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

添加到收藏夹

Article Chemistry, Medicinal

Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders

Xufen Yu et al.

Summary: AKT, a critical node in the PI3K/AKT/m-TOR signaling pathway, is strongly correlated with cancer. Two novel and potent AKT degraders were identified, showing the ability to induce AKT protein degradation and inhibit cancer cell proliferation.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Chemistry, Medicinal

Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems

Xiaojuan Qu et al.

Summary: PROTAC technology offers a promising strategy to target EGFR protein and overcome drug resistance in non-small cell lung cancer patients with EGFR mutations. The involvement of autophagy/lysosome system in PROTAC-mediated target protein degradation is demonstrated in this study, providing new insights into cancer treatment.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Cell Biology

A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models

Xufen Yu et al.

Summary: This study proposes pharmacological degradation of WDR5 as a promising therapeutic strategy for treating WDR5-dependent tumors and presents two high-resolution crystal structures of WDR5-degrader-E3 ligase ternary complexes. The designed WDR5 degrader, MS67, potently and selectively depleted WDR5, demonstrating higher efficacy than WDR5 PPI inhibitors in suppressing transcription of WDR5-regulated genes and inhibiting cancer cell proliferation. These findings suggest structure-based design can effectively identify highly active degraders for potential treatment of WDR5-dependent cancers.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Mutant-selective degradation by BRAF-targeting PROTACs

Shanique Alabi et al.

Summary: This study developed a vemurafenib-based PROTAC that induces degradation of all classes of BRAF mutants without affecting wild-type RAF proteins. The new therapy demonstrates high selectivity and shows promising inhibitory effects on cancer cell growth in vivo.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Jacqulyne P. Robichaux et al.

Summary: The study characterized the mutational landscape in 16,715 patients with EGFR-mutant NSCLC and established the structure-function relationship of EGFR mutations on drug sensitivity. EGFR mutations can be separated into four distinct subgroups based on sensitivity and structural changes, predicting patient outcomes following treatment with EGFR inhibitors better than traditional exon-based groups. This structure-based approach delineates functional groups of EGFR mutations that can effectively guide treatment choices and suggest potential improvement in prediction of drug sensitivity to targeted therapies in oncogenes with diverse mutations.

NATURE (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

The PROTACtable genome

Melanie Schneider et al.

Summary: This article presents a systematic approach to assessing the PROTAC tractability of protein targets, which could support decision-making on whether a particular target may be amenable to modulation using a PROTAC.

NATURE REVIEWS DRUG DISCOVERY (2021)

添加到收藏夹

Article Oncology

AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway-Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B

Jia Xu et al.

Summary: Through degrading AKT and AURKB proteins, MS21 can inhibit tumor growth, especially in patients with mutations in the PI3K-PTEN pathway but not the RAS pathway.

CANCER DISCOVERY (2021)

添加到收藏夹

Review Oncology

Advancing targeted protein degradation for cancer therapy

Brandon Dale et al.

Summary: The development of small-molecule degraders such as proteolysis-targeting chimeras (PROTACs) has enabled the targeting of previously considered undruggable oncoproteins. This review discusses recent advances in the field, with a focus on opportunities and challenges for future development.

NATURE REVIEWS CANCER (2021)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)

Hao Zhang et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders

Meng Cheng et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

添加到收藏夹

Article Chemistry, Medicinal

Design and synthesis of selective degraders of EGFRL858R/T790M mutant

Xin Zhang et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of Selective Small Molecule Degraders of BRAF-V600E

Xiao-Ran Han et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

添加到收藏夹

Article Chemistry, Multidisciplinary

Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations

Jaebong Jang et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)

添加到收藏夹

Article Chemistry, Medicinal

Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide

Kailun He et al.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Functional characterization of a PROTAC directed against BRAF mutant V600E

Ganna Posternak et al.

NATURE CHEMICAL BIOLOGY (2020)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of potent small molecule PROTACs targeting mutant EGFR

Hong-Yi Zhao et al.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)

添加到收藏夹

Article Oncology

Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study

Camille Mehlman et al.

LUNG CANCER (2019)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Targeted protein degradation: expanding the toolbox

Matthieu Schapira et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

添加到收藏夹

Article Chemistry, Medicinal

Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer

Xin Han et al.

JOURNAL OF MEDICINAL CHEMISTRY (2019)

添加到收藏夹

Review Cell Biology

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

Tatsuya Nagano et al.

CELLS (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

George M. Burslem et al.

CELL CHEMICAL BIOLOGY (2018)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Induced protein degradation: an emerging drug discovery paradigm

Ashton C. Lai et al.

NATURE REVIEWS DRUG DISCOVERY (2017)

添加到收藏夹

Review Chemistry, Multidisciplinary

Small-Molecule Modulation of Protein Homeostasis

George M. Burslem et al.

CHEMICAL REVIEWS (2017)

添加到收藏夹

Review Oncology

Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives

Joan Minguet et al.

INTERNATIONAL JOURNAL OF CANCER (2016)

添加到收藏夹

Review Chemistry, Multidisciplinary

Small-Molecule PROTACS: New Approaches to Protein Degradation

Momar Toure et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M

Kenneth S. Thress et al.

NATURE MEDICINE (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Phthalimide conjugation as a strategy for in vivo target protein degradation

Georg E. Winter et al.

SCIENCE (2015)

添加到收藏夹

Article Oncology

Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma

Gang Lin et al.

ONCOLOGY LETTERS (2015)

添加到收藏夹

Article Oncology

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer

H. J. Lee et al.

BRITISH JOURNAL OF CANCER (2015)

添加到收藏夹

Article Chemistry, Medicinal

Structure-Guided Design and Optimization of Small Molecules Targeting the Protein Protein Interaction between the von Hippel- Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities

Carles Galdeano et al.

JOURNAL OF MEDICINAL CHEMISTRY (2014)

添加到收藏夹

Article Oncology

Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: A meta-analysis of randomized controlled clinical trials

Ning Zhao et al.

LUNG CANCER (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Overexpression of EGFR in Head and Neck Squamous Cell Carcinoma Is Associated with Inactivation of SH3GL2 and CDC25A Genes

Guru Prasad Maiti et al.

PLOS ONE (2013)

添加到收藏夹

Article Oncology

Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer -: A review of the literature

Antonio Araujo et al.

ONCOLOGIST (2007)

添加到收藏夹

Article Oncology

The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors

Jeffrey A. Engelman et al.

CLINICAL CANCER RESEARCH (2006)

添加到收藏夹

Article Oncology

EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus

M Hanawa et al.

INTERNATIONAL JOURNAL OF CANCER (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.